We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: schizophrenia
MedXY News
EnglishTag

schizophrenia

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction
Neurologyschizophrenia

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction

By MedXY|Oct 27, 2025

This study reveals region- and size-specific dendritic spine deficits in cortical layer 3 neurons of schizophrenia patients, highlighting differential synaptic disruptions across visual and prefrontal cortical areas underpinning cognitive d

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT
Diabetes & Endocrinologyobesityprediabetes

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY|Oct 22, 2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study
Internal Medicineadverse eventsantipsychotics

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

By MedXY|Oct 18, 2025

This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
Clinical Updatesauditory verbal hallucinationsneuromodulation

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence

By MedXY|Oct 9, 2025

This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonst

Clozapine and Infection Risk in Schizophrenia: Insights from a Hong Kong Population Study
PsychiatryclozapineInfection Risk

Clozapine and Infection Risk in Schizophrenia: Insights from a Hong Kong Population Study

By MedXY|Oct 4, 2025

This study reveals an increased risk of infections among schizophrenia patients treated with clozapine compared to olanzapine, highlighting the need for vigilant infection monitoring and preventive care.

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
Clinical UpdatesPharmacokineticsschizophrenia

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY|Oct 1, 2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Clinical Updatesclinical trialclozapine

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY|Oct 1, 2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Comparative Analysis of Virtual Reality Therapies for Psychotic Symptoms: Auditory Hallucinations vs. Persecutory Delusions
AIauditory verbal hallucinationsschizophrenia

Comparative Analysis of Virtual Reality Therapies for Psychotic Symptoms: Auditory Hallucinations vs. Persecutory Delusions

By MedXY|Oct 1, 2025

Two randomized controlled trials evaluated immersive VR therapies targeting auditory verbal hallucinations and persecutory delusions in schizophrenia and psychosis, revealing modest benefits for hallucinations but no superior effect for cog

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities